SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.
On August 14, 2024, at 11:00 a.m. PDT/ 2:00 p.m. EDT, Trey Martin, Chief Executive Officer, will participate in a panel discussion of the Critical Components of the Genomic Medicine Supply Chain at the UBS Genomic Medicine Conference in Dana Point, CA.
On September 4, 2024, at 6:30 a.m. PDT/ 9:30 a.m. EDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston, MA.
On September 5, 2024, at 1:50 p.m. PDT/ 4:50 p.m. EDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY.
A live webcast of each presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events, Upcoming events. An archived version of the webcast will also be available on the Maravai website after the event is completed.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Contact Information:
Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.37 |
Daily Change: | -0.06 -1.10 |
Daily Volume: | 2,059,804 |
Market Cap: | US$761.680M |
December 05, 2024 November 07, 2024 November 07, 2024 September 24, 2024 August 28, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB